Vaccine by itself will not end coronavirus pandemic: WHO Chief
Geneva/IBNS: World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus on Monday said a vaccine would not by itself stop the coronavirus pandemic and cannot replace the other tools.
In a tweet, he said: A vaccine on its own will not end the COVID19 pandemic. We will still need to continue."
A vaccine on its own will not end the #COVID19 pandemic. We will still need to continue:
— Tedros Adhanom Ghebreyesus (@DrTedros) November 16, 2020
-Surveillance
-Testing, isolating & caring for cases
-Tracing & quarantining contacts
-Engaging communities
-Encouraging individuals to be careful #ACTogether #EB147
"Since the beginning of the COVID19 pandemic, we knew that a vaccine would be essential for bringing the pandemic under control. But it’s important to emphasise that a vaccine will complement the other tools we have, not replace them."
Initial supply of #COVID19 vaccines will be limited, so #healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move. #EB147
— Tedros Adhanom Ghebreyesus (@DrTedros) November 16, 2020
The remarks come on a day when American biotechnology company Moderna, Inc, said that its vaccine candidate against COVID-19 has shown 94.5 per cent efficiency.
The WHO chief mentioned that: "Initial supply of COVID19 vaccines will be limited, so healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move."
Initial supply of #COVID19 vaccines will be limited, so #healthworkers, older people & other at-risk populations will be prioritised. That will hopefully reduce the number of deaths & enable health systems to cope, but the virus will still have a lot room to move. #EB147
— Tedros Adhanom Ghebreyesus (@DrTedros) November 16, 2020
Moderna's study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).
Welcoming the progress, Stéphane Bancel, Chief Executive Officer of Moderna, said: “This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."
Bancel said, “This milestone is only possible because of the hard work and sacrifices of so many."
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.